Education
About Us
Working with TipRanks
Follow Us
Cytek Biosciences (CTKB)
NASDAQ:CTKB
CTKB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.00 - $7.63
Previous CloseN/A
Volume141.86K
Average Volume (3M)902.37K
Market Cap
$538.01M
Enterprise Value$491.90M
Total Cash (Recent Filing)$98.72M
Total Debt (Recent Filing)$7.55M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
May 07, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding128,097,380
10 Day Avg. Volume1,075,815
30 Day Avg. Volume902,370
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.68
Price to Cash Flow (P/CF)67.40
P/FCF Ratio67.40
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.43
Enterprise Value/Ebitda-49.02
Forecast
1Y Price Target
$7.13Price Target Upside69.76% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Cytek Biosciences News
PremiumCompany Announcements
Cytek Biosciences Reports Mixed Earnings Amid Growth and Challenges
PremiumCompany Announcements
Cytek Biosciences Reports Growth and Strategic Expansion---
Bulls Say, Bears Say
Bulls Say
International Market GrowthManagement spoke to strong growth in Asia Pacific and Rest Of World markets as key sources of optimism for FY25.
Product DemandStrong demand observed for the Aurora Cell Sorter, indicating healthy market interest.
Service RevenueService revenue grew +8% y/y to $12.5M driven by growth in the instrument installed base.
Bears Say
Competitive PressureIncreased competition from companies with larger R&D budgets and commercial reach is impacting Cytek Biosciences' ability to gain market share.
Export ControlsNew U.S. export controls on biotech equipment to China may impact Cytek Biosciences' growth despite strong performance.
NIH FundingGeopolitical concerns and uncertainty regarding NIH funding create challenges for Cytek Biosciences, which has significant exposure to the global academic and government market.
---
Ownership Overview
9.16% Insiders
16.68% Mutual Funds
13.95% Other Institutional Investors
38.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CTKB FAQ
What was Cytek Biosciences’s price range in the past 12 months?
Cytek Biosciences lowest stock price was $4.00 and its highest was $7.63 in the past 12 months.
What is Cytek Biosciences’s market cap?
Cytek Biosciences’s market cap is $538.01M.
When is Cytek Biosciences’s upcoming earnings report date?
Cytek Biosciences’s upcoming earnings report date is May 07, 2025 which is in 44 days.
How were Cytek Biosciences’s earnings last quarter?
Cytek Biosciences released its earnings results on Feb 27, 2025. The company reported $0.121 earnings per share for the quarter, beating the consensus estimate of $0.103 by $0.018.
Is Cytek Biosciences overvalued?
According to Wall Street analysts Cytek Biosciences’s price is currently Undervalued.
Does Cytek Biosciences pay dividends?
Cytek Biosciences does not currently pay dividends.
What is Cytek Biosciences’s EPS estimate?
Cytek Biosciences’s EPS estimate is -0.03.
How many shares outstanding does Cytek Biosciences have?
Cytek Biosciences has 128,097,380 shares outstanding.
What happened to Cytek Biosciences’s price movement after its last earnings report?
Cytek Biosciences reported an EPS of $0.121 in its last earnings report, beating expectations of $0.103. Following the earnings report the stock price went down -6.653%.
Which hedge fund is a major shareholder of Cytek Biosciences?
Currently, no hedge funds are holding shares in CTKB
---
Cytek Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.13 (69.76% Upside)
$7.13 (69.76% Upside)
Blogger Sentiment
Bullish
CTKB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 238.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ―
Last 30 Days ―
Last 30 Days ―
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.45%
12-Months-Change
Fundamentals
Return on Equity
-1.53%
Trailing 12-Months
Asset Growth
0.89%
Trailing 12-Months
Company Description
Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.
---
CTKB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a mix of achievements and challenges. Cytek Biosciences experienced revenue and adjusted EBITDA growth, driven by international market success and increased service revenues. However, flat product revenue, challenges in the U.S. market, and potential headwinds from NIH funding reductions and currency exchange rates present concerns.Read More>---
CTKB Stock 12 Month Forecast
Average Price Target
$7.13
▲(69.76% Upside)
Technical Analysis
Best Analysts Covering CTKB
1 Year
1 Year Success Rate
2/22 ratings generated profit
1 Year Average Return
-24.49%
reiterated a buy rating 21 days ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -24.49% per trade.
---